论文部分内容阅读
Purpose: To evaluate the activity of dendritic cells-cytokine induced killer (DCs-CIK) cells infusion as an adjuvant therapy for colorectal carcinoma patients combined with first-line treatment.Methods: A total of 142 patients with stage Ⅲ/Ⅳ colorectal carcinoma who treated with first-line therapy were studied retrospectively.